Goldman Sachs Group Inc Arbutus Biopharma Corp Transaction History

Goldman Sachs Group Inc

$780 Billion
Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,173,430 shares of ABUS stock, worth $9.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,173,430

Previous 3,039,783 28.5%

Holding current value

$9.82 Million

Previous $9.39 Million 5.06%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$3.08 - $4.9 $2.67 Million - $4.25 Million	-866,353 Reduced 28.5%	2,173,430 $9.87 Million
Q2 2025 Aug 14, 2025	BUY	$2.88 - $3.61 $2.78 Million - $3.48 Million	963,835 Added 46.43%	3,039,783 $9.39 Million
Q1 2025 May 09, 2025	BUY	$3.06 - $3.59 $4.72 Million - $5.54 Million	1,544,070 Added 290.31%	2,075,948 $7.25 Million
Q4 2024 Feb 11, 2025	SELL	$3.18 - $4.2 $90,722 - $119,821	-28,529 Reduced 5.09%	531,878 $1.74 Million
Q3 2024 Nov 14, 2024	BUY	$3.12 - $4.56 $1.26 Million - $1.84 Million	403,078 Added 256.2%	560,407 $2.16 Million

Q2 2024 Aug 13, 2024	SELL	$2.52 - $3.63 $43,787 - $63,074	-17,376 Reduced 9.95%	157,329 $486,000
Q1 2024 May 15, 2024	BUY	$2.26 - $2.92 $108,739 - $140,495	48,115 Added 38.01%	174,705 $450,000
Q4 2023 Feb 13, 2024	SELL	$1.69 - $2.54 $131,902 - $198,244	-78,049 Reduced 38.14%	126,590 $316,000
Q3 2023 May 14, 2024	BUY	$1.9 - $2.27 $148,293 - $177,171	78,049 Added 61.65%	204,639 $415,000
Q3 2023 Nov 14, 2023	SELL	$1.9 - $2.27 $33,206 - $39,672	-17,477 Reduced 7.87%	204,639 $415,000
Q2 2023 May 14, 2024	SELL	$2.24 - $3.06 $108,588 - $148,339	-48,477 Reduced 17.92%	222,116 $510,000
Q2 2023 Aug 14, 2023	SELL	$2.24 - $3.06 $108,588 - $148,339	-48,477 Reduced 17.92%	222,116 $510,000
Q1 2023 May 14, 2024	SELL	$2.23 - $3.1 $252,832 - $351,471	-113,378 Reduced 29.53%	270,593 $819,000
Q1 2023 May 11, 2023	SELL	$2.23 - $3.1 $252,832 - $351,471	-113,378 Reduced 29.53%	270,593 $819,000
Q4 2022 May 14, 2024	SELL	$1.91 - $2.85 $510,094 - $761,135	-267,065 Reduced 41.02%	383,971 $894,000
Q4 2022 Feb 13, 2023	SELL	$1.91 - $2.85 $510,094 - $761,135	-267,065 Reduced 41.02%	383,971 $894,000
Q3 2022 May 14, 2024	SELL	$1.88 - $2.88 $150,642 - $230,771	-80,129 Reduced 10.96%	651,036 $1.24 Million
Q3 2022 Nov 10, 2022	SELL	$1.88 - $2.88 $150,642 - $230,771	-80,129 Reduced 10.96%	651,036 $1.24 Million
Q2 2022 May 14, 2024	BUY	$1.98 - $3.17 $1.2 Million - $1.92 Million	604,575 Added 477.59%	731,165 $1.98 Million
Q2 2022 Aug 15, 2022	SELL	$1.98 - $3.17 $1.6 Million - $2.57 Million	-810,020 Reduced 52.56%	731,165 $1.98 Million
Q1 2022 May 16, 2022	BUY	$2.42 - $3.98 $2.05 Million - $3.37 Million	847,914 Added 122.31%	1,541,185 $4.59 Million
Q4 2021 Feb 14, 2022	BUY	$3.11 - $4.61 $1.26 Million - $1.87 Million	406,635 Added 141.86%	693,271 $2.7 Million
Q3 2021 Nov 10, 2021	BUY	$2.65 - $4.62 $759,585 - $1.32 Million	286,636 New	286,636 $1.23 Million

Others Institutions Holding ABUS

# of Institutions

194

Shares Held

118M

Call Options Held

2.67M

Put Options Held

693K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $678M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Arbutus Biopharma Corp Transaction History